Quoin Pharmaceuticals
QNRX
8 hedge funds and large institutions have $183K invested in Quoin Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
300% more funds holding
Funds holding: 2 → 8 (+6)
73% more capital invested
Capital invested by funds: $106K → $183K (+$77.6K)
0.09% more ownership
Funds ownership: 0.06% → 0.15% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$187K |
| 2 |
Renaissance Technologies
New York
|
+$131K |
| 3 |
VF
Virtu Financial
New York
|
+$86.7K |
| 4 |
HF
HRT Financial
New York
|
+$85.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$100K |
| 2 |
LA
LM Advisors
San Diego,
California
|
-$78 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
Altium Capital Management
New York
| $62.9K | +$187K | +1,893 | New |
|
|
2
Renaissance Technologies
New York
| $44K | +$131K | +1,329 | New |
|
|
VF
3
Virtu Financial
New York
| $29K | +$86.7K | +879 | New |
|
|
HF
4
HRT Financial
New York
| $28K | +$85.4K | +866 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $10.2K | +$30.4K | +308 | New |
|
6
UBS Group
Zurich,
Switzerland
| $4.85K | +$14.4K | +146 | New |
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $3.6K | +$7.79K | +79 | +263% |
|
8
JP Morgan Chase
New York
| $612 | +$1.78K | +18 | New |
|
|
HNB
9
Huntington National Bank
Columbus,
Ohio
| $6 | – | – | – |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$100K | -599 | Closed |
|
|
LA
11
LM Advisors
San Diego,
California
| – | -$78 | – | – |
|
QNRX Hedge Fund Activity: Q1 2024 in Review
8 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2024, worth a combined $183K — up 73% from $106K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new QNRX positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $187K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $100K sold.
- 8 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q1 2024, up from 2 in Q4 2023.
- Funds reported $183K of Quoin Pharmaceuticals stock for Q1 2024, up 73% quarter-over-quarter.
- 7 funds opened new Quoin Pharmaceuticals positions in Q1 2024 and 1 closed out, a net change of +6 holders.
- The largest Quoin Pharmaceuticals buyer in Q1 2024 was Altium Capital Management, an estimated $187K added.
- The largest Quoin Pharmaceuticals seller in Q1 2024 was Susquehanna International Group, an estimated $100K sold.
Based on aggregated 13F filings for Q1 2024.